Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that balding dermal papilla cells show premature senescence and altered expression of stress and DNA damage markers, suggesting sensitivity to environmental stress in androgenetic alopecia.

Minoxidil promotes hair growth in male pattern baldness.

In their study, Tim Spector and colleagues identified a new genetic association at chromosome 20p11.22 with male-pattern baldness, confirmed by the increased risk when combined with a known androgen receptor gene variant.

Minoxidil helped bald patient regrow hair.

Young men with male pattern baldness lose hair density over time without treatment.

Women with thinning hair have thinner hair strands than women without hair loss.

This study found that 4 weeks of finasteride treatment significantly decreased DHT levels in bald scalp to levels similar to hair-containing scalp in men with male pattern baldness.

Lowest effective minoxidil concentration is 1%, but 2% works better for male pattern baldness.

This review discusses the role of Prostaglandin D2 and its synthase in androgenetic alopecia but reports no new clinical findings, suggesting pathways for future therapeutic development.

In this study, minoxidil treatment was associated with an increase in nonvellus scalp hairs, but this effect was not sustained once the treatment was stopped.

This study found no support for the idea that male-pattern baldness in female-to-male transsexuals indicates an increased risk of coronary heart disease through androgenic effects on classic risk factors.

Minoxidil effectively regrows hair in male pattern baldness.

This study found that men with rapidly progressive male pattern baldness had elevated serum dehydroepiandrosterone sulfate levels, suggesting that adrenal hyperactivity may contribute to alopecia in genetically susceptible young men.

This study found that sebaceous glands in bald scalp have greater androgen binding affinity and capacity than those in hairy scalp, possibly contributing to the androgenic response seen in male pattern baldness.

This study found that twice-daily application of 3% topical minoxidil maintained a higher nonvellus hair count compared to once-daily application over 2 years and 9 months in men with male pattern baldness.

This study suggests that the HDAC9 gene is a third susceptibility gene for male-pattern baldness, with significant associations found in both German and Australian samples.

This study suggests that Botox injections may increase hair count and reduce hair loss in men with androgenetic alopecia, potentially through increased blood flow and oxygen to the scalp.

High testosterone to epitestosterone ratio in hair could predict male-pattern baldness.

In this study, women with diffuse alopecia were found to have higher serum levels of adrenal androgen DHEAS, which may contribute to disrupted scalp hair growth.

This study found that topical minoxidil increased heart rate and had significant effects on cardiac volumes and mass compared to placebo, but its long-term safety remains uncertain.

This study suggests that the AGA risk haplotype in Europeans was driven to high frequency by positive selection, likely associated with a variant in the EDA2R gene.

This study observed that 2% minoxidil solution was at least as effective as 3% for increasing hair growth and stabilizing bald areas in men with male pattern baldness.

This review addresses the limited efficacy of current treatments for male pattern baldness and explains that emerging genetic insights could lead to more effective future therapies.

Minoxidil helps some bald men, but most lose hair again when stopping.

This study suggests that the AR/EDA2R locus may contribute to early-onset female pattern hair loss, but no association was found with the 20p11 locus.

This study found that early-onset androgenic alopecia is associated with a higher risk of developing prostate cancer, although it was not linked to earlier diagnosis or more aggressive tumors.

This study identified histologic lesions and a defect in adhesion molecules causing hair loss in mice with the bal mutation, linked to a mutation in the desmoglein 3 gene.

In a study using human scalp skin grafts on SCID mice, topical flutamide and finasteride significantly improved hair growth in male-pattern baldness compared to placebo, with flutamide showing superior results to finasteride.

Injecting platelet-rich plasma (PRP) can increase hair growth rate and density in male pattern baldness.

This study found that minoxidil increased 17ß-hydroxysteroid dehydrogenase activity by nearly 40% in dermal papilla cells from balding scalps but not in nonbalding scalp cells or dermal fibroblasts.